Delineating the role of c-FLIP/NEMO interaction in the CD95 network via rational design of molecular probes.


Journal

BMC genomics
ISSN: 1471-2164
Titre abrégé: BMC Genomics
Pays: England
ID NLM: 100965258

Informations de publication

Date de publication:
08 May 2019
Historique:
entrez: 10 12 2019
pubmed: 10 12 2019
medline: 6 2 2020
Statut: epublish

Résumé

Structural homology modeling supported by bioinformatics analysis plays a key role in uncovering new molecular interactions within gene regulatory networks. Here, we have applied this powerful approach to analyze the molecular interactions orchestrating death receptor signaling networks. In particular, we focused on the molecular mechanisms of CD95-mediated NF-κB activation and the role of c-FLIP/NEMO interaction in the induction of this pathway. To this end, we have created the homology model of the c-FLIP/NEMO complex using the reported structure of the v-FLIP/NEMO complex, and rationally designed peptides targeting this complex. The designed peptides were based on the NEMO structure. Strikingly, the experimental in vitro validation demonstrated that the best inhibitory effects on CD95-mediated NF-κB activation are exhibited by the NEMO-derived peptides with the substitution D242Y of NEMO. Furthermore, we have assumed that the c-FLIP/NEMO complex is recruited to the DED filaments formed upon CD95 activation and validated this assumption in silico. Further insight into the function of c-FLIP/NEMO complex was provided by the analysis of evolutionary conservation of interacting regions which demonstrated that this interaction is common in distinct mammalian species. Taken together, using a combination of bioinformatics and experimental approaches we obtained new insights into CD95-mediated NF-κB activation, providing manifold possibilities for targeting the death receptor network.

Sections du résumé

BACKGROUND BACKGROUND
Structural homology modeling supported by bioinformatics analysis plays a key role in uncovering new molecular interactions within gene regulatory networks. Here, we have applied this powerful approach to analyze the molecular interactions orchestrating death receptor signaling networks. In particular, we focused on the molecular mechanisms of CD95-mediated NF-κB activation and the role of c-FLIP/NEMO interaction in the induction of this pathway.
RESULTS RESULTS
To this end, we have created the homology model of the c-FLIP/NEMO complex using the reported structure of the v-FLIP/NEMO complex, and rationally designed peptides targeting this complex. The designed peptides were based on the NEMO structure. Strikingly, the experimental in vitro validation demonstrated that the best inhibitory effects on CD95-mediated NF-κB activation are exhibited by the NEMO-derived peptides with the substitution D242Y of NEMO. Furthermore, we have assumed that the c-FLIP/NEMO complex is recruited to the DED filaments formed upon CD95 activation and validated this assumption in silico. Further insight into the function of c-FLIP/NEMO complex was provided by the analysis of evolutionary conservation of interacting regions which demonstrated that this interaction is common in distinct mammalian species.
CONCLUSIONS CONCLUSIONS
Taken together, using a combination of bioinformatics and experimental approaches we obtained new insights into CD95-mediated NF-κB activation, providing manifold possibilities for targeting the death receptor network.

Identifiants

pubmed: 31815628
doi: 10.1186/s12864-019-5539-y
pii: 10.1186/s12864-019-5539-y
pmc: PMC6900753
doi:

Substances chimiques

CASP8 and FADD-Like Apoptosis Regulating Protein 0
IKBKG protein, human 0
Molecular Probes 0
NF-kappa B 0
fas Receptor 0
I-kappa B Kinase EC 2.7.11.10

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

293

Références

Proc Natl Acad Sci U S A. 2005 Jul 19;102(29):10147-52
pubmed: 16006526
Mol Syst Biol. 2011 Oct 11;7:539
pubmed: 21988835
Cell Death Differ. 2012 Jan;19(1):36-41
pubmed: 22075988
J Mol Biol. 1993 Dec 5;234(3):779-815
pubmed: 8254673
Mol Cell. 2012 Jul 27;47(2):291-305
pubmed: 22683266
Exp Cell Res. 2012 Jul 1;318(11):1324-31
pubmed: 22309778
Mol Biol Evol. 2016 Jun;33(6):1635-8
pubmed: 26921390
Mol Cell. 2016 Oct 20;64(2):236-250
pubmed: 27746017
Cell Death Differ. 2016 Apr;23(4):681-94
pubmed: 26494467
J Biol Chem. 2015 Jul 3;290(27):16539-49
pubmed: 25979343
J Virol. 2017 Nov 14;91(23):
pubmed: 28931678
Curr Biol. 2007 Aug 21;17(16):1438-43
pubmed: 17702576
Trends Mol Med. 2017 Dec;23(12):1138-1155
pubmed: 29128367
Cell Cycle. 2013 Jan 15;12(2):193-4
pubmed: 23287476
Mol Cell. 2017 Feb 16;65(4):715-729.e5
pubmed: 28212752
J Immunol Methods. 2015 Aug;423:12-7
pubmed: 25967949
Mol Cell. 2012 Jul 27;47(2):306-19
pubmed: 22683265
Mol Biol Evol. 2017 Jul 1;34(7):1812-1819
pubmed: 28387841
Mol Cell. 2013 Mar 28;49(6):1034-48
pubmed: 23434371
Mol Syst Biol. 2010;6:352
pubmed: 20212524
EMBO J. 2004 Aug 4;23(15):3175-85
pubmed: 15272306
J Cell Biol. 2010 Aug 9;190(3):377-89
pubmed: 20696707
J Exp Med. 2006 May 15;203(5):1295-305
pubmed: 16682493
Exp Cell Res. 2015 Nov 15;339(1):1-9
pubmed: 26453936
Semin Cell Dev Biol. 2015 Mar;39:26-34
pubmed: 25655947
J Biol Chem. 2016 Apr 1;291(14):7608-20
pubmed: 26865630
Mol Cell. 2008 Jun 6;30(5):620-31
pubmed: 18538660

Auteurs

Nikita V Ivanisenko (NV)

The Federal Research Center Institute of Cytology and Genetics SB RAS, Novosibirsk, Russia.
Novosibirsk State University, Novosibirsk, Russia.

Jörn H Buchbinder (JH)

Translational Inflammation research, Medical Faculty, Otto von Guericke University, Magdeburg, Germany.

Johannes Espe (J)

Translational Inflammation research, Medical Faculty, Otto von Guericke University, Magdeburg, Germany.

Max Richter (M)

Translational Inflammation research, Medical Faculty, Otto von Guericke University, Magdeburg, Germany.

Miriam Bollmann (M)

Translational Inflammation research, Medical Faculty, Otto von Guericke University, Magdeburg, Germany.

Laura K Hillert (LK)

Translational Inflammation research, Medical Faculty, Otto von Guericke University, Magdeburg, Germany.

Vladimir A Ivanisenko (VA)

The Federal Research Center Institute of Cytology and Genetics SB RAS, Novosibirsk, Russia.
Novosibirsk State University, Novosibirsk, Russia.

Inna N Lavrik (IN)

The Federal Research Center Institute of Cytology and Genetics SB RAS, Novosibirsk, Russia. inna.lavrik@med.ovgu.de.
Translational Inflammation research, Medical Faculty, Otto von Guericke University, Magdeburg, Germany. inna.lavrik@med.ovgu.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH